Table 1. Clinical data of PB-DLBCL patients.

Patient	Age	Laterality	Nodal involvement	Stage	IPI	Chemo-therapy	Cycles	Radio-therapy	Response to treatment	Relapse	Treatment	Time to progression	Response to treatment
01	84	Left	No	IE	2	R-CVP	5	Yes	CR
02	78	Right	No	IE	1	R-CHOP	4	No	CR
03	74	Left	No	IE	2	R-CHOP	4	No	CR
04	40	Right	Yes	IIE	0	R-CHOP	4	Yes	CR
05	60	Left	No	IE	1	R-CHOP	8	No	CR
06	29	Right	No	IE	0	R-CHOP	6	No	CR
07	78	Bilateral	Yes	IIE	1	R-CHOP	6	No	CR
08	73	Left	No	IE	2	CHOP	6	No	CR
09	75	Left	No	IE	1	R-CHOP	4	No	CR
10	79	Left	No	IE	2	R-CHOP	6	No	CR
11	83	Right	Yes	IIE	2	R-MVP	6	No	CR	Nodal	No treatment	7 m	Progression
12	70	Right	No	IE	1	R-CHOP	6	No	CR	Contralateral breast	R-ESHAP	80 m	CR
13	79	Left	No	IE	1	R-CHOP	4	Yes	CR
14	62	Right	No	IE	1	R-CHOP	4	Yes	CR	Brain	Methotrexate	23 m	Progression
15	70	Left	No	IE	2	R-CHOP	6	No	CR
16	46	Left	Yes	IIE	ND	R-CHOP	6	No	CR
17	42	Right	Yes	IIE	ND	R-CHOP	6	Yes	CR	Contralateral breast	R-COMP	157 m	CR

Abbreviations: R-CVP: Rituximab, Cyclophosphamide, Vincristine, Prednisone; R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; R-MVP: Rituximab, Methotrexate, Vincristine, Procarbazine; R-COMP: Rituximab, Cyclophosphamide, Myocet, Prednisone; R-ESHAP: Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin; CR: Complete response; ND: No data; m: months